The market has been high on Zai Lab Ltd - ADR (ZLAB) stock recently. ZLAB gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With ZLAB Stock Today?
Zai Lab Ltd - ADR (ZLAB) stock is lower by -1.75% while the S&P 500 has risen 0.25% as of 11:15 AM on Thursday, Apr 8. ZLAB is lower by -$2.37 from the previous closing price of $135.28 on volume of 112,866 shares. Over the past year the S&P 500 is up 53.80% while ZLAB has risen 158.80%. ZLAB lost -$3.46 per share in the over the last 12 months.
To screen for more stocks like Zai Lab Ltd - ADR click here.
More About Zai Lab Ltd - ADR
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatment across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC. The other product candidate includes Fugan, ZL-2302, and ZL-1101. The company operates through the segment being Developing and commercializing proprietary therapeutics.
Click Here to get the full Stock Score Report on Zai Lab Ltd - ADR (ZLAB) Stock.
